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Background: The presence of diabetes and plasma glucose concentration on admission are associated with
adverse outcomes after an acute myocardial infarction (AMI), as high glucose can induce vascular endothelial cell
apoptosis. This study explored the relative associations among admission plasma glucose level, soluble Fas (sFas)
concentration, and long-term survival in patients with acute ST-elevation myocardial infarction (STEMI).
Methods: This prospective cohort study include 83 patients with acute STEMI. Based on their admission plasma
glucose levels (7.8 and 11.1 mmol/L as the limits for low and high levels, respectively), patients were allocated into
one of three groups: normal glucose (n = 33), median glucose (n = 24), and high glucose (n = 26). The admission
plasma level of sFas was measured with a sandwich enzyme-linked immunosorbent assay (ELISA). Patients were
followed up for an average of 89 ± 20 months for all causes of death and cardiovascular death.
Results: sFas levels were significantly higher in the high glucose group compared to the normal glucose group
(5.87 ± 1.70 mmol/L vs. 3.07 ± 0.93 mmol/L, respectively, P < 0.05). The sFas level was positively associated with the
admission plasma glucose level. The correlation coefficient (R) was 0.747, and R2 was 0.559. Mortality was
significantly higher in the high glucose group compared to the normal glucose group (19.2% vs. 3.0%, respectively,
P < 0.05).
Conclusions: In patients with acute STEMI, plasma glucose level was high on admission, and sFas apoptosis levels
were increased. Long-term follow-up revealed that a high admission plasma glucose level was associated with
higher mortality compared to a normal admission glucose level.
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Acute myocardial infarction (AMI) is a major cause of
mortality throughout the world. Electrocardiography can
be used to classify AMI as an ST elevation myocardial
infarction (STEMI) or as a non-ST elevation myocardial
infarction (non-STEMI) [1]. More than three million pa-
tients are reportedly diagnosed with STEMI each year
[2]. The in-hospital mortality of STEMI patients in the* Correspondence: linzhangpeking@hotmail.com
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countries varies from 6% to 14% [3].
There are many clinical trials and animal studies on
AMI. Several investigators have described apoptosis after
AMI in humans. Recent studies suggest that Fas apop-
tosis system activation may play a pathogenic role in
AMI and therefore may be a valuable diagnostic tool
[4-6].
Diabetes is an independent predictor of mortality after
AMI [7]. However, some patients with AMI are unaware
that they have abnormal glucose metabolism, have not
undergone an oral glucose tolerance test, and do not
have a diagnosis of diabetes. The relationship betweenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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needs to be studied. Some studies have recently reported
that STEMI patients with high glucose at admission are
at an increased risk of 30-day and 1-year mortality [8].
The poor prognosis of patients who are diabetic or
who have a high glucose level is related to many factors.
Myocardial cell apoptosis is one possible reason, and
the Fas/Fas ligand (Fas/FasL) complex may play a role
in the process. In the present study, we initially exam-
ined the relationship between the admission plasma
glucose level and soluble Fas (sFas) concentration, then
we investigated the effect of different admission plasma
glucose levels on mortality.
Methods
Experimental design and subjects
This prospective cohort trial was carried out at the
Heart Center of the Chao-Yang Hospital at the Capital
Medical University (Beijing, China). The research proto-
col was reviewed and approved by the Medical Ethics
Committee of the Capital Medical University Chao-Yang
Hospital. All patients provided informed consent to par-
ticipate after they were informed of risks associated with
the study verbally and in writing. Male and female pa-
tients (older than 18 years) were selected for participa-
tion based on the following criteria: chest pain lasting
30 min or longer, ST elevation greater than 0.1 mV in at
least two contiguous precordial leads, or at least two
adjacent limb leads on the electrocardiogram or evidence
of new onset left-bundle branch block. Patients wereFigure 1 Patient flow diagram. Patients with acute ST-elevation myocard
plasma glucose level. Three patients were lost to follow up, and eight patieexcluded for the following reasons: previous myocardial
infarction, valvular heart disease, autoimmune disease,
infective disease, tumor, or serious liver or kidney dysfunc-
tion (i.e., serum creatinine level greater than 170 μmol/L
or an alanine aminotransferase level greater than three
times the normal upper limit).
Patient allocation
A total of 83 consecutive patients were allocated to the
normal, median, or high admission plasma glucose group
for glucose levels of < 7.8 mmol/L, between 7.8 and
11.1 mmol/L, or ≥11.1 mmol/L, respectively (Figure 1).
All included patients remained in their allocated groups
during the follow-up period.
Interventions
All patients were administered clopidogrel (300 mg) and
aspirin (300 mg) 10–40 min before catheterization and
underwent routine primary percutaneous coronary in-
tervention (PCI). Coronary angiography (CA) was per-
formed using the standard Seldinger technique, in order to
demonstrate the absence of coronary collaterals in the risk
region and to locate the site of occlusion in the infarct rela-
tive artery. The number of blocked coronary vessels and
the location of stenosis were recorded. Revascularization
was performed by direct stenting. The number of stents
implanted, and the type of stent used (bare-metal or drug-
eluting) were also recorded. Patients were then monitored
in the coronary care unit (CCU) for 1–3 days. Discharge
medications for each patient included aspirin, β-blockers,ial infarction were divided into three groups based on their admission
nts died within the follow-up period.
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or angiotensin-receptor blockers (ARBs).
Data collection and follow up
Each patient’s hospitalization data were recorded in ac-
cordance with the protocol. On hospital admission, 3 mL
blood was withdrawn from an antecubital vein. Samples
were collected into prechilled evacuation tubes containing
ethylenediaminetetra-acetic acid (EDTA). The samples
were centrifuged at 2000 rpm in a BECKMAN CS-15R
centrifuge (Beckman Coulter, Brea, CA, USA) for 10 min
and stored at −70°C until the assay was performed. sFas
plasma levels were measured with a sandwich enzyme-
linked immunosorbent assay (ELISA) kit: Human Fas
(CD95)/TNFRSF6 Quantikine ELISA Kit (R&D Systems
Inc., Minneapolis, MN, USA).
Patients were followed up by telephone from the day
of acute STEMI admission until death, emigration, or
the end of study on September 8, 2013. The predefined
primary outcome was all-cause mortality. Data concern-
ing whether the patient died, when death occurred, and
the cause of death were registered. Meanwhile, the num-
bers of rehospitalizations for CA were retrospectively
analyzed at the end of the follow-up period.
Statistical analysis
Categorical data are presented as proportions. Groups
were compared with chi-square analyses. Continuous
data are presented as the mean ± standard deviation
(SD). Comparison of the groups by analysis of variance
(ANOVA) was followed by Newman-Keuls multiple
comparison analysis to determine differences between
individual groups. A P value < 0.05 for two-tailed tests
was considered significant. Kaplan–Meier analysis was
performed to estimate the 8 years follow-up mortality.
SPSS version 18.0 software was used for statistical calcu-
lations (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 83 eligible consecutive patients with primary
acute STEMI were included between April 2005 and
December 2005. Patients were divided into three groups
based on their admission plasma glucose level. There
were 33, 24, and 26 patients in the normal, median, and
high glucose groups, respectively (Figure 1). There were
no significant differences in the discharge medication or
the proportion of patients with hypertension or other
cardiovascular risk factors. The difference in glycosylated
hemoglobin (HbA1C) level among the groups was sig-
nificantly different (P < 0.05). Triglycerides were signifi-
cantly higher in the high glucose group compared to the
normal glucose group (P < 0.05) (Table 1).All patients were accepted for primary PCI and moni-
tored in the CCU for 1–3 days. Discharge medications
for each patient included aspirin, β-blockers, statins,
ACE inhibitors, or ARBs. Three patients were lost to fol-
low up, eight patients died within the 8-year follow-up
period, and seven of the eight patients suffered a cardio-
vascular death (Figure 1).
Correlation between the admission plasma glucose
and sFas levels
The sFas levels of all patients were determined by ELISA.
There was a significant difference among the three groups
(Table 2). The sFas levels were higher in the high glucose
group (5.87 ± 1.70 ng/mL; 95% confidence interval [CI],
5.14-6.51) than in the normal glucose group (3.07 ±
0.93 ng/mL; 95% CI, 2.74-3.40) (P < 0.05), and they were
elevated in the median glucose group (4.84 ±1.38 ng/mL;
95% CI: 4.25-5.42) compared to the normal glucose group
(3.07 ± 0.93 ng/mL) (P < 0.05). There was no significant
difference in sFas level between the high and median
glucose groups. The scatter plot of the admission plasma
glucose and sFas levels shows a positive association; the
correlation coefficient (R) was 0.747, R2 was 0.559, and the
regression line equation was Y = 1.225 + 0.327X (P < 0.05)
(Figure 2).
Follow up after acute STEMI
All patients were followed up for an average of 89 ±
20 months. The normal, median, and high admission
plasma glucose level groups were followed for 90 ±
21 months, 90 ± 20 months, and 87 ± 21 months, respect-
ively. The normal and high admission plasma glucose
groups lost one and two patients to follow up, respectively.
In the normal, median, and high glucose groups, one, two,
and five patients died, which corresponded to mortality
rates of 3.0%, 8.3%, and 19.2%, respectively. There was a
significant difference between the normal and high plasma
glucose groups (P < 0.05). The Kaplan-Meier survival
curves are shown in Figure 3.
All patients rehospitalized for CA were retrospectively
analyzed at the end of the follow-up. In total, 11 patients
were rehospitalized for CA, owing to angina or re-
infarction. The numbers of patients receiving in-stent
re-stenosis in the normal, median, and high glucose
groups, were one, two, and two, respectively, and the
rates of in-stent re-stenosis in these three groups were
25%, 50%, and 67%, respectively.
Discussion
It was reported that nearly two-thirds of patients with
cardiovascular disease suffer from abnormal glucose me-
tabolism [9,10]. In-hospital measurements of HbA1C
and admission plasma glucose may be useful as early
markers of long-standing glucometabolic disturbance
Table 1 Baseline characteristics
Normal glucose group Median glucose group High glucose group
(n = 33) (n = 24) (n = 26)
Age (y) 58 ± 11 61 ± 10 59 ± 11
Male (%) 28 (84.8%) 20 (83.3%) 18 (69.2%)
BMI (kg/m2) 25.3 ± 1.8 25.0 ± 2.7 25.7 ± 2.5
Medical history
Hypertension, n (%) 20 (60.6%) 19 (79.2%) 21 (80.8%)
Previous diabetes, n (%) 2 (6.1%) 6 (25.0%) 12 (46.2%)*
Previous angina, n (%) 5 (15.1%) 3 (12.5%) 3 (11.5%)
Atrial fibrillation, n (%) 0 (0%) 0 (0%) 1 (3.8%)
Current smoker, n (%) 21 (63.3%) 15 (62.5%) 20 (76.9%)
Biochemical data
Cholesterol (mmol/L) 4.81 ± 0.85 4.46 ± 1.13 4.80 ± 1.21
LDL-cholesterol (mmol/L) 2.78 ± 0.68 2.57 ± 0.75 2.78 ± 0.83
HDL-cholesterol (mmol/L) 1.02 ± 0.22 0.95 ± 0.26 0.96 ± 0.21
Triglycerides (mmol/L) 1.31 ± 0.65 1.27 ± 0.83 1.98 ± 1.42*
hsCRP (mg/L) 3.2 ± 2.8 2.3 ± 1.6 3.7 ± 4.5
CKMB (IU/L) 137.9 ± 96.9 145.7 ± 85.5 100.6 ± 89.5
Creatinine (μmol/L) 91.48 ± 29.34 85.04 ± 26.74 96.15 ± 19.31
GFR (ml/min) 78.22 ± 24.28 79.43 ± 27.45 70.90 ± 15.85
HbA1C (%) 4.5 ± 1.1 5.3 ± 1.2† 7.6 ± 2.0*, #
Admission plasma glucose level (mmol/L) 6.3 ± 0.9 9.1 ± 0.9† 14.5 ± 3.4*, #
Clinical aspects of STEMI
Ischemia time
Symptom-to-enrollement, min 355 ± 162 340 ± 151 346 ± 180
Symptom-to-ballon, min 419 ± 159 409 ± 149 414 ± 183
Infarct site: Anterior 51.5% 54.2% 57.7%
Infarct related artery
LAD, n (%) 18 (55%) 11 (46%) 13 (50%)
LCX, n (%) 3 (9%) 3 (13%) 3 (11%)
RCA, n (%) 12 (36%) 10 (42%) 10 (38%)
Number of diseased vessels
1 coronary vessel (%) 23 (70%) 17 (71%) 16 (62%)
2 coronary vessels (%) 8 (24%) 6 (25%) 8 (31%)
3 coronary vessels (%) 2 (6%) 1 (4%) 2 (7%)
Number of stent implanted 1.48 ± 0.51 1.58 ± 0.50 1.50 ± 0.51
Stent type
Bare-metal stent, (%) 44% 39% 38%
Drug-eluting stent, (%) 56% 61% 62%
BMI body mass index; HDL high-density lipoprotein; hsCRP high-sensitivity C-reactive protein; LDL low-density lipoprotein; CKMB creatine kinase isoenzyme MB;
GFR glomerular filtration rate; HbA1C glycosylated hemoglobin;
*P < 0.05 for the high glucose group versus the normal glucose group.
#P < 0.05 for the high glucose group versus the median glucose group.
†P < 0.05 for the median glucose group versus the normal glucose group.
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(n = 33) (n=24) (n=26)
Soluble fas
(ng/mL)
3.07 ± 0.93 4.84 ± 1.38# 5.87 ± 1.70*
*P < 0.05 for the high glucose group versus the normal glucose group;
#P < 0.05 for the median glucose group versus the normal glucose group.
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glucose concentration are associated with adverse out-
comes after an AMI. Gholap et al. [12] found that the
admission glucose level was strongly associated with
mortality in all presentations of AMI, irrespective of
whether a diabetes diagnosis had previously been estab-
lished. However, the follow-up periods in previous
reports were brief [8,12]; there are few long-term follow-
up studies of acute STEMI patients with high admission
plasma glucose levels.
In the current study, patients with acute STEMI were
divided into three groups based on their admission plasma
glucose level. All patients were followed up for an average
of 89 ± 20 months. The mortality rate was higher in the
high admission plasma glucose group than in the normal
group (19.2% vs. 3.0%, respectively, P < 0.05). Kaplan-
Meier survival curves depict the high mortality rate in theFigure 2 Correlation between the admission glucose level and the sF
improvement in the admission glucose level. The correlation coefficient R i
Y = 1.225 + 0.327X (P < 0.05).high admission glucose level group and suggest that prog-
nosis is poor for acute STEMI patients with an admission
plasma glucose level higher than 11.1 mmol/L.
It has been suggested that high levels of plasma glu-
cose at hospital admission is positively associated with
rates of in-stent re-stenosis and poor prognosis [13,14].
In the present study, we did not repeat CA for evaluat-
ing the rates of in-stent re-stenosis at follow-up, because
it is an invasive method that requires in-hospital treat-
ment and increases treatment costs. In addition, patients
without symptoms were unwilling to accept repeat CA.
The rate of in-stent re-stenosis was a secondary rather
than primary outcome in clinical follow up. In the
present study, patients were followed up for the primary
end-point outcomes, (all-cause mortality and cardiovas-
cular mortality), in order to identify the relationship be-
tween plasma glucose concentrations and the apoptosis
marker sFas upon admission and at the first end-point
outcome after acute STEMI.
There is a growing body of studies on the relationship
between high plasma glucose levels and heart health
[15-19]. Most previous studies have found that a high
glucose level induces or aggravates myocardial injury.
High ambient glucose disturbs the cell cycle, increases
DNA damage, delays endothelial cell replication, and
causes excessive cell death [19]. Several studies fromas level. We found that sFas levels increased in accordance with
s 0.747, the R2 is 0.559, with a regression line equation of
Figure 3 Kaplan-Meier survival curves of acute ST-elevation myocardial infarction patients with different admission plasma glucose
levels. Mortality was higher in the high glucose level group than the normal glucose level group (P < 0.05).
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mediates endothelial cell to chondrocyte transition in
human aortic tissue, and selectively triggers apoptosis in
cultured endothelial cells [15,19]. During apoptosis, or
programmed cell death, cells gradually lose their normal
morphology and undergo genomic DNA degradation
that is not associated with necrosis. The existing data
indicate that apoptosis plays an important role in myocar-
dial ischemia in both humans and animal models [20].
Fas was identified as a valuable biomarker of the
physiological response to ischemia [4,5]. Patients with
AMI who experience hypoxia undergo apoptotic myo-
cardial cell death that is associated with increased serum
concentrations of sFas. This correlation of cell death
with serum concentrations of Fas and sFas in AMI pa-
tients suggests that Fas-mediated cardiomyocyte apop-
tosis is involved in disease pathology [21].
Kageyama et al. [22] found that the exposure of
human coronary artery endothelial cells to a high glu-
cose environment significantly increased Fas expression.
Coronary vessels from type 2 diabetic mice displayedappreciable expression levels of tumor necrosis factor
receptor 1 (TNF-R1) and Fas [22]. The present study
demonstrated that sFas levels were significantly higher
in the high admission glucose level group compared to
the normal glucose level group (P < 0.05), and sFas con-
centration was positively associated with admission
plasma glucose level (P < 0.05).
Limitations
A limitation of this study is that it was performed in a small
patient sample at a single center. We were unable to divide
the subjects into subgroups, which may have influenced the
statistical power of our analyses. There were fewer data for
in-stent re-stenosis, as the number of repeat CA cases at
follow-up were not included. Further studies are needed to
expand the sample size, including the number of repeat CA
cases at follow-up, and to confirm these findings.
Conclusion
The results of this study indicate that in patients with
acute STEMI, sFas concentration is positively associated
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was increased in patients with high glucose levels at ad-
mission glucose, and these patients had higher mortality
on long-term follow up compared to those with normal
glucose levels at admission.
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